

Transcriptomic Analysis of the Effect of Glabridin on Biofilm Formation in Staphylococcus Aureus

A. INTRODUCTION

Staphylococcus aureus, particularly methicillin-resistant strains (MRSA), remains a major global health threat due to its ability to form robust biofilms that protect bacteria from antibiotics and the host immune system. These biofilms contribute significantly to chronic infections and the rapid spread of multi-drug resistance, rendering many conventional treatments ineffective. Glabridin (Glb), a natural flavonoid extracted from licorice/akar manis (*Glycyrrhiza glabra*), has emerged as a promising antimicrobial candidate with known antiviral and antibacterial properties. However, the precise molecular mechanisms by which it disrupts *S. aureus* biofilms remain largely unexplored. This study aims to evaluate the antibiofilm efficacy of Glabridin and elucidate its underlying regulatory pathways, offering a potential novel strategy to combat the escalating challenge of bacterial resistance.

B. METHODS

Preparation & MIC Testing	Biofilm & Growth Analysis	Structural & Matrix Evaluation	Genetic & Molecular Validation
Identify MRSA strains and determine the Minimum Inhibitory Concentration (MIC) of Glabridin to find the exact dose that affects behavior without killing the bacteria.	Perform Crystal Violet assays to measure biofilm reduction and monitored growth curves to ensure Glabridin was specifically targeting the biofilm rather than inhibiting cell viability.	Scanning Electron Microscopy (SEM) was used to visualize physical changes in the biofilm architecture Agarose gel electrophoresis was performed to measure the inhibition of eDNA (the "glue" of the matrix).	RNA sequencing (RNA-seq) was conducted to map gene expression changes RT-qPCR to confirm the downregulation of master regulators like <i>sarA</i> and <i>icaD</i> .

C. RESULTS

1. Non-Toxic Biofilm Inhibition

Glabridin effectively inhibits the formation of *S. aureus* biofilms at sub-inhibitory concentrations (1/2, 1/4, and 1/8 MIC) without killing the bacteria or affecting their normal growth rate.

2. Structural Disruption

Scanning Electron Microscopy (SEM) images show that Glabridin disrupts the physical architecture of the biofilm, leading to a significant reduction in bacterial adhesion and a thinner, more scattered biofilm layer.

3. eDNA Reduction

The treatment significantly suppresses the secretion of extracellular DNA (eDNA), which is a vital "glue" that holds the biofilm matrix together.

4. Transcriptomic Impact

RNA-seq analysis identified 184 differentially expressed genes (DEGs), showing that Glabridin triggers a broad genetic response in the bacteria.

5. Downregulation of Key Regulators

Glabridin downregulates critical global regulatory genes, specifically *sarA*, which is essential for biofilm development.

6. Inhibition of Matrix & Virulence Genes

There is a marked decrease in the expression of genes responsible for biofilm synthesis (*icaD*) and those related to bacterial virulence (*hla*), which reduces the bacteria's ability to cause infection.

7. Metabolic Modulation

